{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:38:34Z","timestamp":1792852714099,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jacbts.2024.12.005","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:45:37Z","timestamp":1739976337000},"page":"786-797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of Factor XI Using RBD4059"],"prefix":"10.1016","volume":"10","author":[{"given":"Junshi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5490-5118","authenticated-orcid":false,"given":"Sofia","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ueckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ming","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2024.12.005_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2024.12.005_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41573-020-0061-0","article-title":"Therapeutic strategies for thrombosis: new targets and approaches","volume":"19","author":"Mackman","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacbts.2024.12.005_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0b013e328309ecbc","article-title":"New anticoagulants","volume":"15","author":"Bauer","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib4","doi-asserted-by":"crossref","first-page":"287S","DOI":"10.1378\/chest.126.3_suppl.287S","article-title":"Hemorrhagic Complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Levine","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jacbts.2024.12.005_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2016.05.007","article-title":"The intrinsic pathway of coagulation as a target for antithrombotic therapy","volume":"30","author":"Wheeler","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jacbts.2024.12.005_bib6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.12.005_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.12.005_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib10","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.12.005_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacbts.2024.12.005_bib12","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.12.005_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/ATVBAHA.117.309664","article-title":"2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis","volume":"38","author":"Weitz","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jacbts.2024.12.005_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008362","article-title":"RNAi therapies: drugging the undruggable","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1261\/rna.2348111","article-title":"Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects","volume":"17","author":"Petri","year":"2011","journal-title":"Rna"},{"issue":"4","key":"10.1016\/j.jacbts.2024.12.005_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/nano7040077","article-title":"siRNA delivery strategies: a comprehensive review of recent developments","volume":"7","author":"Tatiparti","year":"2017","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jacbts.2024.12.005_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/srep00787","article-title":"Characterization of coagulation factor synthesis in nine human primary cell types","volume":"2","author":"Dashty","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacbts.2024.12.005_bib20","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1073\/pnas.0703778104","article-title":"Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes","volume":"104","author":"Rozema","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2024.12.005_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00001721-199703000-00008","article-title":"A murine model of factor XI deficiency","volume":"8","author":"Gailani","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacbts.2024.12.005_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacbts.2024.12.005_bib24","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"10.1016\/j.jacbts.2024.12.005_bib25","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1124\/dmd.119.087098","article-title":"In vitro drug-drug interaction evaluation of GalNAc Conjugated siRNAs against CYP450 enzymes and transporters","volume":"47","author":"Ramsden","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacbts.2024.12.005_bib26","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc\u2013siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2024.12.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107405","article-title":"Antidotes for reversal of direct oral anticoagulants","volume":"204","author":"Dobesh","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacbts.2024.12.005_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2516.1995.tb00080.x","article-title":"Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate","volume":"1","author":"Collins","year":"1995","journal-title":"Haemophilia"},{"key":"10.1016\/j.jacbts.2024.12.005_bib29","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.12.005_bib30","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jth.15744","article-title":"First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men","volume":"20","author":"Nowotny","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacbts.2024.12.005_bib31","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacbts.2024.12.005_bib32","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jacbts.2024.12.005_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.12.023","article-title":"Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency","volume":"163","author":"Salloum-Asfar","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacbts.2024.12.005_bib34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.14740\/jh522","article-title":"Hemophilia C: a case report with updates on diagnosis and management of a rare bleeding disorder","volume":"8","author":"Jayakrishnan","year":"2019","journal-title":"J Hematol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1751-553X.2010.01261.x","article-title":"The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies","volume":"33","author":"Bowyer","year":"2011","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jacbts.2024.12.005_bib36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI Antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib38","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2024.12.005_bib40","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2024.12.005_bib41","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2024.12.005_bib42","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2024.12.005_bib43","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"24","key":"10.1016\/j.jacbts.2024.12.005_bib44","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ajhp\/zxae182","article-title":"Exploring the therapeutic utility of the factor XIa inhibitor asundexian","volume":"81","author":"Edwards","year":"2024","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacbts.2024.12.005_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2023.08.001","article-title":"A new strategy for anticoagulation: the factor XI inhibitors","volume":"116","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacbts.2024.12.005_bib46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1089\/nat.2022.0010","article-title":"Cross-species translation of biophase half-life and potency of GalNAc-conjugated siRNAs","volume":"32","author":"Boianelli","year":"2022","journal-title":"Nucleic Acid Ther"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X24004534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X24004534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:58:18Z","timestamp":1750690698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X24004534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2452302X24004534"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.005","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Factor XI Using RBD4059","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2024.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}